ClinicalTrials.gg
RecruitingNCT06907602ONTRESCCUpdated Apr 2, 2025

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

A Phase 2/3 interventional study of Chemotherapy and Immunotherapy (Pembrolizumab) in Locally Advanced Esophageal Squamous Cell Carcinoma, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Peking Union Medical College Hospital · Phase 2/3, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jan 2024, registered Mar 2025).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 402 studies in Esophageal Squamous Cell Carcinoma with a site in China — 175 open to participants now, 214 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Planned enrollment
114th of 352
120 · median 70
Started
2024
with 50 others
Phase 2/3
10 of 402
6 open now
Primary completion
2026-12
later than 109 of 213 live
Registered
318th of 402
by date

Among the 402 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 114th largest by planned enrollment of the 352 interventional ones that give a count, is one of 51 that started in 2024, is one of 10 in phase 2/3, reaches primary completion later than 109 of the 213 other live ones, and was the 318th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

175 of the 402 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

170 more — sign in →

All 175 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

Our previous study, a single-center, prospective, single-arm Phase II study (Keypoint001) has demonstrated the efficacy and safety of neoadjuvant chemotherapy combined with immunotherapy in locally advanced (cT3-4N+M0) esophageal squamous cell carcinoma. The results show that the pathological complete response rate (pCR) reaches 35%, and the major pathological response rate is over 70%, which is much higher than that of patients receiving chemotherapy alone. Meanwhile, no severe adverse drug reactions have been found in terms of safety, so this treatment regimen is safe and reliable.

However, the cycle of neoadjuvant immunotherapy is still under exploration. Currently, the mainstream research centers adopt a regimen of 2 to 4 cycles. The exploration results of our center have found that most patients' conditions can be further alleviated after 4 cycles compared with after 2 cycles, but there are still a small number of patients with no obvious remission. Therefore, we consider observing whether patients with no obvious remission can achieve a better pathological response rate through further radiotherapy.

03

Conditions studied

  • Locally Advanced Esophageal Squamous Cell Carcinoma

Keywords

  • esophageal squamous cell carcinoma
  • neoadjuvant chemoimmunotherapy
  • radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female
  • Age ≥ 18 years old
  • Pathological confirmation of esophageal squamous cell carcinoma
  • Endoscopic ultrasound, enhanced CT scan of the neck, chest, and abdomen, and esophageal magnetic resonance imaging evaluate as T3 or resectable T4 PET/CT、 Cervical, thoracic, and abdominal enhanced CT evaluation of N0 or N+
  • No clear distant (M0) and only cervical or supraclavicular lymph node metastasis (M1a)
  • Tumor longitudinal diameter ≤ 10cm
  • The tumor did not involve the dentate line
  • score 0 or 1
  • No hematological diseases, no liver or kidney dysfunction
  • ≥ 1.5 × 109/L
  • ≥ 100 × 109/L
  • ≥ 11g/L
  • ≤ 2 times the value
  • TBil ≤ 1.5 times the upper limit of normal value
  • rate (Cockroft) ≥ 50ml/min
  • Obtain

Exclusion criteria

Exclusion Criteria:

  • T staging evaluation is T1/T2
  • PET/CT and other evaluations show distant (M1)
  • Planned pregnancy or patients during pregnancy or lactation
  • History of previous chemotherapy, radiation therapy, or immunotherapy
  • Previous severe coronary heart disease and heart failure ( grade III/IV)
  • Previous pulmonary interstitial fibrosis or severe pulmonary dysfunction that cannot tolerate surgery
  • Previous disease requiring systemic treatment within 2 years
  • Previous immunodeficiency diseases or the need for systemic replacement therapy
  • Previous motor or sensory neurotoxic diseases
  • Previous mental illness
  • Potential diseases that may affect patients' ability to receive planned treatment, such as drug allergies
  • Acute infectious diseases requiring systemic treatment
  • Previous , , or infections
  • Previously received stem cell or solid organ transplantation
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    2 cycles chemoimmunotherapy plus surgery

    2 cycles chemoimmunotherapy and surgery

    Drug: Chemotherapy · Drug: Immunotherapy (Pembrolizumab)

  • Experimental
    4 cycles chemoimmunotherapy plus surgery

    4 cycles chemoimmunotherapy and surgery

    Drug: Chemotherapy · Drug: Immunotherapy (Pembrolizumab)

  • Experimental
    4 cycles chemoimmunotherapy plus radiotherapy and surgery

    4 cycles chemoimmunotherapy plus radiotherapy and surgery

    Drug: Chemotherapy · Drug: Immunotherapy (Pembrolizumab) · Radiation: radiotherapy

Interventions

  • DrugChemotherapy

    carboplatin plus nab-paclitaxel

  • DrugImmunotherapy (Pembrolizumab)

    Pembrolizumab

  • Radiationradiotherapy

    40-45Gy/20fx,5 times a week

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Pathological response

    Postoperative pathology according to CAP classification.

    Time frame: After surgery

  2. 2-year and 5-year overall survival

    overall survival after 2 years and 5 years

    Time frame: 2 years and 5 years after therapy

Secondary outcomes

  1. Adverse effect incidence

    Adverse effect according to CTCAE and RTOG criteria

    Time frame: 1 years after therapy

  2. R0 resection rate

    Time frame: After surgery

  3. postoperative complications

    postoperative complications according to Clavien-Dindo classification

    Time frame: After surgery

  4. 2-year and 5-year disease-free survival

    disease-free survival after 2 years and 5 years

    Time frame: 2 years and 5 years after therapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 2, 2025
StartActual
Jan 12, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06907602
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Jan 12, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 2, 2025

Study contacts

Li Li
Contact
Lili4037@pumch.cn
+86-10-69152630

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion